Please assess the completion status of the following clinical trial:

Trial Title: Promoting Tolerance to Peanut in High-Risk Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Able to consume solid food~* Allergy to eggs and/or severe eczema~* Informed consent obtained from parent or guardian.~Exclusion Criteria:~* Clinically significant chronic illness. Participants with eczema or recurrent wheeze are not excluded.~* Positive skin prick test for peanut allergen with a wheel diameter greater than 4 mm in the presence of a negative saline control~* Previous or current consumption of peanut protein that exceeds 0.2 g of peanut protein on at least one occasion or 0.5 g over a single week~* Investigator-suspected allergy to peanut protein~* Investigator-suspected allergy to peanut protein in care provider or current household member.~* Diagnosis of persistent asthma~* ALT (SGPT) or bilirubin greater than 2 times the upper limit of age-related normal value~* BUN or creatinine greater than 1.25 times the upper limit of age-related normal value~* Platelet count less than 100,000/mL, hemoglobin less than 9 g/dL, or investigator-suspected immunocompromise~* Unwillingness or inability to comply with study requirements and procedures

- Gender: ALL
- Minimum Age: 4 Months
- Maximum Age: 10 Months
- Healthy Volunteers: f

Study Arms:
- Peanut Consumption Group (Type: EXPERIMENTAL): Participants on this arm will consume peanut protein.
- Peanut Avoidance Group (Type: NO_INTERVENTION): Participants on this arm will avoid peanut as per United Kingdom (UK) public health recommendations.

Based on this trial design, predict the completion outcome and termination type (if applicable).